Eton Launches U.S. Commercial Availability of IMPAVIDO
DEER PARK, Ill. — September 28, 2026 Eton Pharmaceuticals, Inc. announced the U.S. commercial launch of IMPAVIDO® (miltefosine) capsules,...
regulatory T cells
Advertisement
Tiziana Doses First Participants in ALS Foralumab Trial
BOSTON, Mass. — September 28, 2026 Tiziana Life Sciences, Ltd. announced that the first three participants have been dosed...
HCW Biologics Strengthens HCW9302 Patent for Alopecia Areata
MIRAMAR, Fla., Sept. 2, 2026 HCW Biologics Inc. (NASDAQ: HCWB), a clinical-stage biopharmaceutical company developing fusion immunotherapeutics for autoimmune...
Daiichi Sankyo Begins Phase 1 Trial of CD25 ADC DS1025
Tokyo, Japan – August 27, 2026 Daiichi Sankyo has entered a new phase of oncology development with the first...
HCW Biologics Advances HCW9302 in Alopecia Areata
MIRAMAR, Fla., August 14, 2026 HCW Biologics Inc. (NASDAQ: HCWB) reported second-quarter 2026 business and clinical development updates, highlighting...
Advertisements
FDA Approves Tregzi to Prevent Chronic GVHD in Blood Cancer
SILVER SPRING, Maryland, June 30, 2026 The U.S. Food and Drug Administration (FDA) has approved Tregzi, the first regulatory...
FDA Approves Tregzi for Chronic GVHD Prevention in Blood Cancer
SILVER SPRING, Maryland, June 30, 2026 The U.S. Food and Drug Administration (FDA) has approved Tregzi, developed by Orca...
Samsung Bioepis Relaunches BYOOVIZ with Harrow in the U.S.
INCHEON, South Korea, July 1, 2026 Samsung Bioepis has officially announced the U.S. relaunch of BYOOVIZ® (ranibizumab-nuna), the first...
FDA Approves Tregzi to Prevent Chronic GVHD in Blood Cancer
SILVER SPRING, Md., June 30, 2026 The U.S. Food and Drug Administration (FDA) has approved Tregzi, the first regulatory...
Coya Therapeutics Begins Blinded Extension Phase of ALSTARS Trial for COYA 302 in ALS
HOUSTON, Texas, June 8, 2026 Coya Therapeutics, Inc. announced a significant milestone in the ongoing ALSTARS clinical trial, with...
Advertisement
